CSL investors see limited direct impact from U.S. pricing deals
UBS analysts cited by market talk say CSL’s U.S. pricing agreements—giving Medicaid access at comparable prices—are unlikely to have much direct financial impact.
CSL's bulls at UBS don't think the Australia-based pharmaceutical company will experience much of a direct financial impact from its U.S. pricing agreements.
CSL has agreed to give Medicaid access to medicines at prices comparable to those in other developed economies, but the investment bank's ana…